Topping the spate of high-dollar collaborations announced Monday, Seattle Genetics Inc. signed Genentech Inc. to a potential $860M partnership to develop SGN-40, a monoclonal antibody in early clinical testing in hematologic cancers. (BioWorld Today) Read More
